Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.46 USD
Change Today -1.04 / -4.08%
Volume 162.7K
ATRC On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:30 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

atricure inc (ATRC) Snapshot

Open
$25.38
Previous Close
$25.50
Day High
$25.59
Day Low
$24.16
52 Week High
08/4/15 - $28.15
52 Week Low
10/8/14 - $13.19
Market Cap
698.0M
Average Volume 10 Days
190.5K
EPS TTM
$-0.72
Shares Outstanding
28.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATRICURE INC (ATRC)

Related News

No related news articles were found.

atricure inc (ATRC) Related Businessweek News

No Related Businessweek News Found

atricure inc (ATRC) Details

AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. The company offers Isolator Synergy ablation system and related radio frequency(RF) ablation devices, which include clamps that are used for ablation during open-heart procedures; ablation and sensing unit, a compact power generator that delivers bipolar RF energy to its clamps, multifunctional pens, and Coolrail linear ablation devices; AtriCure Switch Box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in clamps; and Coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. It also provides Isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias; perform temporary cardiac pacing, sensing, and stimulation; and ablate cardiac tissue with the same device. In addition, the company provides Fusion surgical ablation system; Estech electrosurgical unit, a compact power generator for use with Fusion ablation products; AFfirm bipolar pacing probes used to test lesions created in surgically treating the patient’s arrhythmia; cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; and AtriClip system that is designed for the left atrial appendage management. Further, it sells enabling technologies, including Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; and Estech cardiac surgery instruments that are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products to hospitals and medical centers through independent distributors and direct sales personnel. AtriCure, Inc. is headquartered in West Chester, Ohio.

320 Employees
Last Reported Date: 03/2/15

atricure inc (ATRC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $265.6K
Chief Operating Officer
Total Annual Compensation: $324.0K
Senior Vice President of Operations & Quality...
Total Annual Compensation: $286.4K
Vice President and General Manager of Interna...
Total Annual Compensation: $272.4K
Compensation as of Fiscal Year 2014.

atricure inc (ATRC) Key Developments

AtriCure, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Fiscal Year 2015

AtriCure, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $32,583,000 compared to $26,514,000 for the same period a year ago. Loss from operations was $4,819,000 compared to $2,853,000 for the same period a year ago. Loss before income tax expense was $4,883,000 compared to $2,687,000 for the same period a year ago. Net loss was $4,891,000 compared to $2,692,000 for the same period a year ago. Basic and diluted net loss per share was $0.18 compared to $0.10 for the same period a year ago. Non-GAAP adjusted loss (adjusted LBITDA) was $1,020,000 compared to $2,537,000 for the same period a year ago. For the six months, the company reported total revenue of $62,469,000 compared to $51,361,000 for the same period a year ago. Loss from operations was $9,963,000 compared to $10,778,000 for the same period a year ago. Loss before income tax expense was $10,143,000 compared to $10,369,000 for the same period a year ago. Net loss was $10,157,000 compared to $10,401,000 for the same period a year ago. Basic and diluted net loss per share was $0.37 compared to $0.40 for the same period a year ago. Net cash used in operating activities was $6,394,000 compared to $18,373,000 for the same period a year ago. Purchases of property and equipment were $4,077,000 compared to $2,475,000 for the same period a year ago. Non-GAAP adjusted loss (adjusted LBITDA) was $3,129,000 compared to $7,235,000 for the same period a year ago. The company projects that 2015 revenue will be in the range of $127 million to $129 million. This compares to previous expectations of 2015 revenue in the range of $123.5 million to $125.5 million. The company projects adjusted EBITDA, a non-GAAP measure, to be a loss in the range of $7 million to $8 million for 2015 in order to continue making strategic investments to drive the long-term growth plan.

AtriCure, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:00 PM

AtriCure, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

AtriCure, Inc. to Report Q2, 2015 Results on Jul 28, 2015

AtriCure, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Jul 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRC:US $24.46 USD -1.04

ATRC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardiovascular Systems Inc $24.08 USD -0.16
CryoLife Inc $9.78 USD -0.12
Endologix Inc $12.98 USD -0.06
Spectranetics Corp/The $16.85 USD -0.36
Vascular Solutions Inc $34.56 USD -0.51
View Industry Companies
 

Industry Analysis

ATRC

Industry Average

Valuation ATRC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATRICURE INC, please visit www.atricure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.